Capivasertib CAPItello-291



## Capivasertib CAPItello-291 PRELIMINARY SCORE CURATIVE **NON-CURATIVE ADJUSTMENTS** Quality of life Reviewed, but not qualified for an ESMO-MCBS credit Serious and disabling adverse effects Other adjustments

Capivasertib CAPItello-291	Capivasertib CAPItello-291	
SCORE		
CURATIVE		
Overall Survival / Disease-Free Survival / Pathologica	al Complete Response	
NON-CURATIVE		
Overall Survival		
3		
Progression-Free Survival		
Non-inferiority (Improved Quality of Life or Reduced A	Adverse Events) / Response Rate	
Overall Response Rate / Duration of Response		
Overall Survival / Disease-Free Survival / Pathologica	al Complete Response	
INFORMATION		
Therapeutic Indication: Capivasertib with fulvest receptor (HR)-positive, human epidermal growth locally advanced or metastatic breast cancer wire alterations, following progression on at least one metastatic setting or recurrence on or within 12 therapy  Experimental Arm: Capivasertib + Fulvestrant Control Arm: Placebo + fulvestrant	n factor receptor 2 (HER2)-negative th one or more PIK3CA/AKT1/PTEN- e endocrine-based regimen in the	



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.